Results 251 to 260 of about 261,128 (338)

Dupilumab Treatment in Pemphigus: A Report of Three Cases and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pemphigus vulgaris (PV) and foliaceus (PF) are rare autoimmune blistering diseases traditionally treated with systemic corticosteroids, immunosuppressants, intravenous immunoglobulins, and rituximab. Nonetheless, a subset of patients remains refractory or has contraindications to these conventional therapies.
José Javier Mateos Rico   +5 more
wiley   +1 more source

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou   +2 more
wiley   +1 more source

Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis? [PDF]

open access: yesArthritis Res Ther
Ito H   +21 more
europepmc   +1 more source

Surgical Procedures and Medical Treatments Among Patients With Hidradenitis Suppurativa Before and After Referral to Specialised Dermatological Hospital Care: A Nationwide Registry Study

open access: yesJEADV Clinical Practice, EarlyView.
Hidradenitis suppurativa (HS) is often diagnosed late, complicating management. In this nationwide Danish study including 10,196 patients with dermatologist‐verified HS, we examined treatment patterns before and after referral to specialised hospital care.
Nana A. L. Rosenø   +8 more
wiley   +1 more source

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy